Literature DB >> 16918820

Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases.

K P Klausen1, H Scharling, J S Jensen.   

Abstract

BACKGROUND: The original definition of microalbuminuria (20-200 microg min-1 or 15-150 microg min-1 overnight) is based on studies of patients with diabetes, in whom microalbuminuria was associated with increased risk of chronic renal failure. In a recent report an overnight urinary albumin excretion (UAE) above only 5 microg min-1 was strongly predictive of coronary heart disease and death in the general population. The aim of the present study was to investigate if this cut-off level also has prognostic value in a population with cardiovascular or cerebrovascular disease. METHODS AND
RESULTS: In The Third Copenhagen City Heart Study in 1992-1994, 491 men and women aged 30-80 years with a history of coronary heart disease or stroke delivered a timed overnight urine sample. They were followed by registers with respect to vital status until 2004. During follow-up, 141 of the 491 participants died. The relative risk of death in subjects with UAE above 5 microg min-1 compared with subjects with lower UAE was 2.0 (1.4-2.8; P<0.001). It was unaffected [RR 1.9 (1.3-2.7); P<0.005] by adjustment for age, sex, blood pressure, diabetes, lipoproteins, renal creatinine clearance, smoking and body mass index.
CONCLUSIONS: Subjects with cardiovascular or cerebrovascular disease have about 100% higher risk of death if microalbuminuria defined as UAE above 5 microg min-1 is present. Measurements of UAE should be included in the risk assessment in subjects with cardiovascular or cerebrovascular disease. This study supports the definition of microalbuminuria as UAE above 5 microg min-1.

Entities:  

Mesh:

Year:  2006        PMID: 16918820     DOI: 10.1111/j.1365-2796.2006.01679.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  18 in total

Review 1.  Chronic kidney disease induced dysfunction of high density lipoprotein.

Authors:  Suguru Yamamoto; Valentina Kon
Journal:  Clin Exp Nephrol       Date:  2013-09-10       Impact factor: 2.801

2.  Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.

Authors:  Suguru Yamamoto; Jiayong Zhong; Patricia G Yancey; Yiqin Zuo; MacRae F Linton; Sergio Fazio; Haichun Yang; Ichiei Narita; Valentina Kon
Journal:  Atherosclerosis       Date:  2015-07-04       Impact factor: 5.162

3.  Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.

Authors:  David B Sacks; Mark Arnold; George L Bakris; David E Bruns; Andrea Rita Horvath; M Sue Kirkman; Ake Lernmark; Boyd E Metzger; David M Nathan
Journal:  Diabetes Care       Date:  2011-06       Impact factor: 19.112

Review 4.  Cardiorenal connection in chronic kidney disease.

Authors:  Sadayoshi Ito
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

5.  Multiple biomarkers and risk of clinical and subclinical vascular brain injury: the Framingham Offspring Study.

Authors:  Aleksandra Pikula; Alexa S Beiser; Charles DeCarli; Jayandra J Himali; Stephanie Debette; Rhoda Au; Jacob Selhub; Geoffrey H Toffler; Thomas J Wang; James B Meigs; Margaret Kelly-Hayes; Carlos S Kase; Philip A Wolf; Ramachandran S Vasan; Sudha Seshadri
Journal:  Circulation       Date:  2012-03-28       Impact factor: 29.690

6.  Dipstick proteinuria as a predictor of all-cause and cardiovascular disease mortality in Bangladesh: A prospective cohort study.

Authors:  Gene R Pesola; Maria Argos; Yu Chen; Faruque Parvez; Alauddin Ahmed; Rabiul Hasan; Muhammad Rakibuz-Zaman; Tariqul Islam; Mahbubul Eunus; Golam Sarwar; Vernon M Chinchilli; Alfred I Neugut; Habibul Ahsan
Journal:  Prev Med       Date:  2015-07-17       Impact factor: 4.018

Review 7.  Cardiovascular high-risk patients--treat to protect, but whom?

Authors:  Faiez Zannad; Anne Jakobsen; Jose Heroys; Ann Ralph; Tomas Rees; Michael Shaw
Journal:  Medscape J Med       Date:  2008-03-26

Review 8.  Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate.

Authors:  Melvin R Hayden; David Goldsmith; James R Sowers; Ramesh Khanna
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

Review 9.  Lipoprotein metabolism in chronic renal insufficiency.

Authors:  Jeffrey M Saland; Henry N Ginsberg
Journal:  Pediatr Nephrol       Date:  2007-03-28       Impact factor: 3.714

10.  Mechanisms for increased cardiovascular disease in chronic kidney dysfunction.

Authors:  Suguru Yamamoto; Valentina Kon
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-05       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.